Vaxart, Inc. (NB11.F)
- Previous Close
0.7070 - Open
0.7010 - Bid 0.6525 x --
- Ask 0.6645 x --
- Day's Range
0.7010 - 0.7010 - 52 Week Range
0.5044 - 1.3875 - Volume
165 - Avg. Volume
487 - Market Cap (intraday)
121.877M - Beta (5Y Monthly) 0.56
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5400 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.50
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
vaxart.comRecent News: NB11.F
Performance Overview: NB11.F
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NB11.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NB11.F
Valuation Measures
Market Cap
121.60M
Enterprise Value
103.18M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.78
Price/Book (mrq)
2.27
Enterprise Value/Revenue
13.98
Enterprise Value/EBITDA
-1.43
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-42.41%
Return on Equity (ttm)
-97.94%
Revenue (ttm)
7.38M
Net Income Avi to Common (ttm)
-82.47M
Diluted EPS (ttm)
-0.5400
Balance Sheet and Cash Flow
Total Cash (mrq)
39.71M
Total Debt/Equity (mrq)
45.87%
Levered Free Cash Flow (ttm)
-40.58M
Research Analysis: NB11.F
Company Insights: NB11.F
NB11.F does not have Company Insights